Covid-19 roundup: The FDA gives Moderna’s Covid-19 team a regulatory embrace to go along with the cheers and jeers; BioNTech expects first coronavirus data in a matter of weeks
The FDA offered a little extra public assurance today that Moderna could expect an open door every time execs come knocking as they piece together their Phase III protocols for an ultra-quick trial launch. The agency has handed fast track status to Moderna for its Covid-19 mRNA vaccine — though with everyone from the president on down clamoring for a definitive end to the pandemic, that may have been a bit unnecessary.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.